HDT Bio Announces Agreement With Korea’s Quratis to Co-Develop Innovative COVID-19 Vaccine in Asia

HDT Bio Announces Agreement With Korea’s Quratis to Co-Develop Innovative COVID-19 Vaccine in Asia




HDT Bio Announces Agreement With Korea’s Quratis to Co-Develop Innovative COVID-19 Vaccine in Asia

  • HDT’s RNA-based vaccine offers simpler manufacturing, greater stability, and vastly lower effective dosing than current mRNA COVID-19 vaccines
  • Deal expands HDT’s network of international partnerships

SEATTLE & SEOUL, South Korea–(BUSINESS WIRE)–HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today an agreement with Korean biotech Quratis Inc. to co-develop HDT’s revolutionary COVID-19 vaccine (a next generation mRNA vaccine) for distribution in South Korea and neighboring countries. HDT previously established a collaboration with Gennova Biopharmaceuticals in India, and it plans to announce similar deals in China and Brazil soon.

“This agreement will enable Quratis to manufacture our next-generation COVID-19 vaccine and distribute it across much of East Asia,” said HDT Bio CEO Steve Reed. “Today, we have advanced both HDT’s business prospects and its global health reach.”

HDT Bio’s COVID-19 vaccine uses a proprietary Lipid InOrganic Nanoparticle (LIONTM) formulation to deliver immune-stimulating RNA fragments to targeted cells. The vaccine, currently in clinical trials to establish safety and efficacy, is significantly different from current mRNA vaccines in two ways. First, its RNA payload is designed to amplify itself inside the body. As a result, the vaccine effectively activates the immune system at a much lower dose than current vaccines, enhancing safety and reducing manufacturing costs. Second, the HDT LION formulation system simplifies manufacture and enhances stability.

“Partnering with HDT Bio gives us a unique opportunity to fight COVID-19 with the world’s most advanced mRNA vaccine technology not only in Korea, but also in other nations in our region to help bring an end to this deadly pandemic,” said Kwan Goo Cho, President of Quratis.

Quratis got an IND approval from Ministry of Food and Drug Safety for Phase I clinical trial of a COVID-19 vaccine in mid-July and is expected to begin evaluating QTP104 in a Phase 1 clinical trial shortly.

ABOUT HDT BIO CORP.

HDT Bio is a Seattle-based biopharmaceutical company dedicated to providing immunotherapies to people around the world, including those in historically underserved areas. The company seeks to harness the body’s immune system to deliver therapies that narrowly target the specific areas of the body where they are needed. HDT’s work focuses on oncological and infectious disease applications. HDT Bio’s founders are world leaders in the development of immune stimulants, including both therapeutics and therapy-enhancing adjuvants. One of the company’s core technologies, RNA/LION™, combines formulation and adjuvant ingredients to stabilize and deliver RNA to the immune system to stimulate responses for therapy or vaccination. http://hdt.bio

ABOUT QURATIS INC.

Established in 2016, Quratis is a biotech company developing vaccines for tuberculosis and other infectious diseases with advanced technologies in adjuvant and antigen discovery. Its technology also includes peptide nucleic acid-based antimicrobial agents which are being developed to treat multi-drug resistant tuberculosis, Staphylococcus aureus infections and cancer. Having recently built cutting-edge GMP-level facilities, Quratis now takes on a leadership’s role in research, development, and manufacturing. For more information, please visit http://www.quratis.com

Contacts

Christopher M. Pirie, Ph.D.

(425)-241-4152

christopher.pirie@hdt.bio